Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression
The receptor tyrosine kinase AXL is a member of the Tyro3-Axl-Mer receptor tyrosine kinase subfamily. AXL affects several cellular functions, including growth and migration. AXL aberration is reportedly a marker for poor prognosis and treatment resistance in various cancers. In this study, we analyz...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Public Library of Science
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839706/ |
| id |
pubmed-4839706 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-48397062016-04-29 Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression Sato, Katsuaki Suda, Kenichi Shimizu, Shigeki Sakai, Kazuko Mizuuchi, Hiroshi Tomizawa, Kenji Takemoto, Toshiki Nishio, Kazuto Mitsudomi, Tetsuya Research Article The receptor tyrosine kinase AXL is a member of the Tyro3-Axl-Mer receptor tyrosine kinase subfamily. AXL affects several cellular functions, including growth and migration. AXL aberration is reportedly a marker for poor prognosis and treatment resistance in various cancers. In this study, we analyzed clinical, pathological, and molecular features of AXL expression in lung adenocarcinomas (LADs). We examined 161 LAD specimens from patients who underwent pulmonary resections. When AXL protein expression was quantified (0, 1+, 2+, 3+) according to immunohistochemical staining intensity, results were 0: 35%; 1+: 20%; 2+: 37%; and 3+: 7% for the 161 samples. AXL expression status did not correlate with clinical features, including smoking status and pathological stage. However, patients whose specimens showed strong AXL expression (3+) had markedly poorer prognoses than other groups (P = 0.0033). Strong AXL expression was also significantly associated with downregulation of E-cadherin (P = 0.025) and CD44 (P = 0.0010). In addition, 9 of 12 specimens with strong AXL expression had driver gene mutations (6 with EGFR, 2 with KRAS, 1 with ALK). In conclusion, we found that strong AXL expression in surgically resected LADs was a predictor of poor prognosis. LADs with strong AXL expression were characterized by mesenchymal status, higher expression of stem-cell-like markers, and frequent driver gene mutations. Public Library of Science 2016-04-21 /pmc/articles/PMC4839706/ /pubmed/27100677 http://dx.doi.org/10.1371/journal.pone.0154186 Text en © 2016 Sato et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Sato, Katsuaki Suda, Kenichi Shimizu, Shigeki Sakai, Kazuko Mizuuchi, Hiroshi Tomizawa, Kenji Takemoto, Toshiki Nishio, Kazuto Mitsudomi, Tetsuya |
| spellingShingle |
Sato, Katsuaki Suda, Kenichi Shimizu, Shigeki Sakai, Kazuko Mizuuchi, Hiroshi Tomizawa, Kenji Takemoto, Toshiki Nishio, Kazuto Mitsudomi, Tetsuya Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression |
| author_facet |
Sato, Katsuaki Suda, Kenichi Shimizu, Shigeki Sakai, Kazuko Mizuuchi, Hiroshi Tomizawa, Kenji Takemoto, Toshiki Nishio, Kazuto Mitsudomi, Tetsuya |
| author_sort |
Sato, Katsuaki |
| title |
Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression |
| title_short |
Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression |
| title_full |
Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression |
| title_fullStr |
Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression |
| title_full_unstemmed |
Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression |
| title_sort |
clinical, pathological, and molecular features of lung adenocarcinomas with axl expression |
| description |
The receptor tyrosine kinase AXL is a member of the Tyro3-Axl-Mer receptor tyrosine kinase subfamily. AXL affects several cellular functions, including growth and migration. AXL aberration is reportedly a marker for poor prognosis and treatment resistance in various cancers. In this study, we analyzed clinical, pathological, and molecular features of AXL expression in lung adenocarcinomas (LADs). We examined 161 LAD specimens from patients who underwent pulmonary resections. When AXL protein expression was quantified (0, 1+, 2+, 3+) according to immunohistochemical staining intensity, results were 0: 35%; 1+: 20%; 2+: 37%; and 3+: 7% for the 161 samples. AXL expression status did not correlate with clinical features, including smoking status and pathological stage. However, patients whose specimens showed strong AXL expression (3+) had markedly poorer prognoses than other groups (P = 0.0033). Strong AXL expression was also significantly associated with downregulation of E-cadherin (P = 0.025) and CD44 (P = 0.0010). In addition, 9 of 12 specimens with strong AXL expression had driver gene mutations (6 with EGFR, 2 with KRAS, 1 with ALK). In conclusion, we found that strong AXL expression in surgically resected LADs was a predictor of poor prognosis. LADs with strong AXL expression were characterized by mesenchymal status, higher expression of stem-cell-like markers, and frequent driver gene mutations. |
| publisher |
Public Library of Science |
| publishDate |
2016 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839706/ |
| _version_ |
1613569082244726784 |